N-Acetylcysteine — Membership Pricing

Other medications in Respiratory & Allergies

• Nintedanib
• Omalizumab
• Pirfenidone
• Prednisolone Systemic
• Roflumilast
• Tezepelumab
• Theophylline
• Beclomethasone

About N-Acetylcysteine

N-acetylcysteine (NAC) is a fascinating compound with diverse applications, from emergency medicine to daily wellness. As a powerful antioxidant precursor, it plays a crucial role in maintaining cellular health. Discover how TheDrugClub can help you access this important medication and supplement at more affordable prices, ensuring you prioritize your well-being without breaking the bank.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What N-Acetylcysteine is approved for (FDA label)

Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with an acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: May 6, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for N-Acetylcysteine (FDA label)

Injection: 6000 mg/30 mL (200 mg/mL) of acetylcysteine in a 30 mL single-dose vial. Injection: 6000 mg/30 mL (200 mg/mL) in a single-dose vial ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: f811ddfc-d7c1-4637-ae81-80c38a77cb80. SPL document ID: 9a22e853-f45c-4bda-87e1-5aaf8e61a225. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for N-Acetylcysteine (FDA label)

Most common adverse reactions (> 2%) are rash, urticaria/facial flushing and pruritus ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience The following clinically significant adverse reactions are described elsewhere in labeling: • Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] • Fluid Overload [see Warnings and Precautions ( 5.2 )] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: f811ddfc-d7c1-4637-ae81-80c38a77cb80. SPL document ID: 9a22e853-f45c-4bda-87e1-5aaf8e61a225. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for N-Acetylcysteine (FDA label)

Acetylcysteine Injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see Warnings and Precautions ( 5.1 )] . Patients with a previous hypersensitivity reaction to acetylcysteine ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: f811ddfc-d7c1-4637-ae81-80c38a77cb80. SPL document ID: 9a22e853-f45c-4bda-87e1-5aaf8e61a225. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for N-Acetylcysteine (FDA label)

• Hypersensitivity Reactions: Fatal or life-threatening anaphylaxis, rash, hypotension, wheezing, shortness of breath and/or bronchospasm have been observed. Observe patients during and after the infusion; immediately discontinue infusion if a serious reaction occurs and initiate appropriate treatment. Acetylcysteine infusion may be carefully restarted after treatment of hypersensitivity has been initiated and acute symptoms have resolved ( 5.1 ). • Fluid Overload : Total volume administered should be reduced for patients weighing less than 40 kg and for those requiring fluid restriction ( 5.2 ). 5.1 Hypersensitivity Reactions Serious acute hypersensitivity reactions including fatal or life-threatening anaphylaxis, rash, hypotension, wheezing, and/or shortness of breath, have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose and occurred soon after initiation of the infusion [ see Adverse Reactions ( 6 ) ]. If a severe hypersensitivity reaction occurs, immediately stop the infusion of acetylcysteine and initiate appropriate treatment.

Source: FDA prescribing information (DailyMed). Set ID: f811ddfc-d7c1-4637-ae81-80c38a77cb80. SPL document ID: 9a22e853-f45c-4bda-87e1-5aaf8e61a225. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.